Therefore, while pre-clinical and clinical evidence suggests that increased signaling of the PTEN/PI3K/Akt pathway is considered to be a sustaining drive in the development and progression of this disease, our understanding of the key biological mediators and microenvironment responses that underpin and define the more aggressive behavior of PTEN-depleted prostate cancer remains to be fully defined. Here, AKT1 is linked to prostate cancer.